China SXT Pharmaceuticals (SXTC) Debt to Equity (2018 - 2025)
China SXT Pharmaceuticals has reported Debt to Equity over the past 8 years, most recently at $0.0 for Q3 2025.
- For Q3 2025, Debt to Equity fell 99.28% year-over-year to $0.0; the TTM value through Sep 2025 reached $0.0, down 99.28%, while the annual FY2025 figure was $0.01, 84.47% down from the prior year.
- Debt to Equity for Q3 2025 was $0.0 at China SXT Pharmaceuticals, down from $0.01 in the prior quarter.
- Over five years, Debt to Equity peaked at $0.76 in Q1 2021 and troughed at $0.0 in Q1 2022.
- A 5-year average of $0.18 and a median of $0.04 in 2024 define the central range for Debt to Equity.
- Biggest five-year swings in Debt to Equity: soared 18592.62% in 2021 and later tumbled 99.91% in 2022.
- Year by year, Debt to Equity stood at $0.15 in 2021, then plummeted by 99.54% to $0.0 in 2022, then soared by 14561.7% to $0.1 in 2023, then skyrocketed by 383.82% to $0.5 in 2024, then plummeted by 99.28% to $0.0 in 2025.
- Business Quant data shows Debt to Equity for SXTC at $0.0 in Q3 2025, $0.01 in Q1 2025, and $0.5 in Q3 2024.